Skip to main content
. 2020 Apr 27;130(6):2872–2887. doi: 10.1172/JCI131842

Figure 6. PLA2G1B acts on dying CD4+ T cells and reduces CD4+ T cell survival.

Figure 6

(A and B) PLA2G1B reduces the survival of human CD4+ T cells. (A) Cells were treated with PBS (Ctrl) or various amounts of PLA2G1B (1, 10, 100 μM) for 1 experiment. Results are shown as the percentage of CD4+ T cell counts normalized to the number of Ctrl cells at each time point. (B) Cells were treated with PBS (Ctrl) or 250 nM PLA2G1B (n = 6 donors). Results are shown as the mean ± SD of the percentage of CD4+ T cell counts normalized to the number of Ctrl cells at each time point. (A and B) The lines show the linear regression and the P values indicate the significance of the difference from control. (C–E) PLA2G1B acts on dying CD4+ T cells and digests phosphatidylserine. FACS analysis of CD4+ T cells for annexin V–APC on Live/Dead marker (Zombie-Violet) positive cells after treatment with (C) 250 nM PLA2G1B WT or H48Q or (D) 250 nM PLA2G1B with anti-PLA2G1B (14G9) or not (without Ab). (C and D) Annexin V–APC labeling (MFI) at various time points after treatment are presented (1 representative experiment of 2 in C and 3 in D is presented). (E) Results are shown as the mean ± SD of the percentage of annexin V–negative Zombie-positive CD4+ T cells after treatment with PBS (Ctrl), PLA2G1B alone (without Ab), or anti-PLA2G1B (14G9) (n = 3 donors). (F) Anti-PLA2G1B treatment inhibits the effect of PLA2G1B on the survival of CD4+ T cells. Results are shown as the mean ± SD of the percentage of CD4+ T cell counts normalized to the number of Ctrl cells at each time point (n = 3 donors). Lines show the linear regression and P values indicate the significance of the difference between experimental conditions. ***P < 0.001.